246 related articles for article (PubMed ID: 37543196)
21. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
22. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
23. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
24. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset.
Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W
Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.
Fang Z; Lin L; Tu Z; Zhu X; Li J; Luo P; Huang K; Wu L
Cancer Med; 2023 Jan; 12(1):712-732. PubMed ID: 35702880
[TBL] [Abstract][Full Text] [Related]
27. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
Xiao Y; Cui G; Ren X; Hao J; Zhang Y; Yang X; Wang Z; Zhu X; Wang H; Hao C; Duan H
Front Oncol; 2020; 10():605737. PubMed ID: 33381460
[TBL] [Abstract][Full Text] [Related]
28. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
29. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
31. Integrin subunit alpha V is a potent prognostic biomarker associated with immune infiltration in lower-grade glioma.
Tan Z; Zhang Z; Yu K; Yang H; Liang H; Lu T; Ji Y; Chen J; He W; Chen Z; Mei Y; Shen XL
Front Neurol; 2022; 13():964590. PubMed ID: 36388191
[TBL] [Abstract][Full Text] [Related]
32. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
33. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
34. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
35. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
Wang H; Wang X; Xu L; Zhang J
Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
[TBL] [Abstract][Full Text] [Related]
36. Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma.
Wang G; Cen Y; Wang C; Xiang W; Li S; Ming Y; Chen L; Zhou J
Transl Cancer Res; 2022 Jun; 11(6):1552-1564. PubMed ID: 35836526
[TBL] [Abstract][Full Text] [Related]
37. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
[No Abstract] [Full Text] [Related]
38. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
[TBL] [Abstract][Full Text] [Related]
39. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
[TBL] [Abstract][Full Text] [Related]
40. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
Qiao Q; Wang Y; Zhang R; Pang Q
Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
